New!
Product Code: 05-PHARM-MTR1-27
From £380.00
Deadline to order: 01/03/2027
EQA Scheme for Detection of MT-RNR1 Variants Associated with Aminoglycoside-Induced Hearing Loss.
NGS, PCR based, Sanger sequencing, Whole exome sequencing, Whole genome sequencing
English, French, German, Italian, Spanish
DNA (in TE Buffer)
No
Jun-27
June - August 2027 (for exact dates see scheme instructions).
December 2027 - January 2028
You can complete purchase on our secure partner site.
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
Two or three mock clinical cases with matching samples. Approximately 1-2µg DNA per sample is provided. Complete information will be available in the scheme instructions.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
